Advertisement

Genitourinary System Cancers

  • Gokhan OzyigitEmail author
  • Pervin Hurmuz
  • Sezin Yuce Sari
  • Cem Onal
  • Fatih Biltekin
  • Melis Gultekin
  • Gozde Yazici
  • Ozan Cem Guler
  • Fadil Akyol
Chapter

Abstract

This chapter on genitourinary cancers is aiming to summarize the evidence-based current management for bladder & prostate cancer. We hope to ease the understanding in the appropriate delineation of tumor volumes/fields along with related case presentations covering diagnostic images, contouring, slice by slice final plan examples; accompanied by up-to-date key literature review.

References

  1. 1.
    Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, et al. ICUD-EAU international consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63(1):45–57.  https://doi.org/10.1016/j.eururo.2012.08.009.PubMedCrossRefGoogle Scholar
  2. 2.
    Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66.  https://doi.org/10.1056/NEJMoa022148.PubMedCrossRefGoogle Scholar
  3. 3.
    Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol. 2003;43(3):246–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys. 2008;70(2):456–63.  https://doi.org/10.1016/j.ijrobp.2007.06.030.PubMedCrossRefGoogle Scholar
  5. 5.
    Munro NP, Sundaram SK, Weston PM, Fairley L, Harrison SC, Forman D, et al. A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK. Int J Radiat Oncol Biol Phys. 2010;77(1):119–24.  https://doi.org/10.1016/j.ijrobp.2009.04.050.PubMedCrossRefGoogle Scholar
  6. 6.
    Hussain SA, Stocken DD, Peake DR, Glaholm JG, Zarkar A, Wallace DM, et al. Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. Br J Cancer. 2004;90(11):2106–11.  https://doi.org/10.1038/sj.bjc.6601852.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Rene NJ, Cury FB, Souhami L. Conservative treatment of invasive bladder cancer. Curr Oncol. 2009;16(4):36–47.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Langsenlehner T, Doller C, Quehenberger F, Stranzl-Lawatsch H, Langsenlehner U, Pummer K, et al. Treatment results of radiation therapy for muscle-invasive bladder cancer. Strahlenther Onkol. 2010;186(4):203–9.  https://doi.org/10.1007/s00066-010-2053-1.PubMedCrossRefGoogle Scholar
  9. 9.
    Hall RR, Newling DW, Ramsden PD, Richards B, Robinson MR, Smith PH. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol. 1984;56(6):668–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol. 1998;16(4):1298–301.  https://doi.org/10.1200/jco.1998.16.4.1298.PubMedCrossRefGoogle Scholar
  11. 11.
    Prout GR Jr, Shipley WU, Kaufman DS, Heney NM, Griffin PP, Althausen AF, et al. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol. 1990;144(5):1128–34. discussion 34–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1996;14(11):2901–7.  https://doi.org/10.1200/jco.1996.14.11.2901.PubMedCrossRefGoogle Scholar
  13. 13.
    Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol. 2007;25(4):303–9.  https://doi.org/10.1016/j.urolonc.2006.09.015.PubMedCrossRefGoogle Scholar
  14. 14.
    Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16(11):3576–83.  https://doi.org/10.1200/jco.1998.16.11.3576.PubMedCrossRefGoogle Scholar
  15. 15.
    Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006;24(35):5536–44.  https://doi.org/10.1200/JCO.2006.07.6729.PubMedCrossRefGoogle Scholar
  16. 16.
    Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005;61(2):420–5.  https://doi.org/10.1016/j.ijrobp.2004.05.074.PubMedCrossRefGoogle Scholar
  17. 17.
    Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11(11):2150–7.  https://doi.org/10.1200/jco.1993.11.11.2150.PubMedCrossRefGoogle Scholar
  18. 18.
    James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88.  https://doi.org/10.1056/NEJMoa1106106.PubMedCrossRefGoogle Scholar
  19. 19.
    Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012;82(3):e457–62.  https://doi.org/10.1016/j.ijrobp.2011.05.051.PubMedCrossRefGoogle Scholar
  20. 20.
    Peyromaure M, Slama J, Beuzeboc P, Ponvert D, Debre B, Zerbib M. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004;63(1):73–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Kragelj B, Zaletel-Kragelj L, Sedmak B, Cufer T, Cervek J. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol. 2005;75(1):44–7.  https://doi.org/10.1016/j.radonc.2005.01.007.PubMedCrossRefGoogle Scholar
  22. 22.
    Aboziada MA, Hamza HM, Abdlrahem AM. Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma. J Egypt Natl Canc Inst. 2009;21(2):167–74.PubMedGoogle Scholar
  23. 23.
    Choudhury A, Cowan R. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer. BJU Int. 2011;108(9):E313.  https://doi.org/10.1111/j.1464-410X.2011.10672_3.x.PubMedCrossRefGoogle Scholar
  24. 24.
    Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011;29(6):733–8.  https://doi.org/10.1200/JCO.2010.31.5721.PubMedCrossRefGoogle Scholar
  25. 25.
    Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18(9):1921–7.  https://doi.org/10.1200/jco.2000.18.9.1921.PubMedCrossRefGoogle Scholar
  26. 26.
    Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705–11.  https://doi.org/10.1016/j.eururo.2011.11.010.PubMedCrossRefGoogle Scholar
  27. 27.
    Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–71.PubMedCrossRefGoogle Scholar
  28. 28.
    Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25(5):783–90.PubMedCrossRefGoogle Scholar
  29. 29.
    Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 2009;73(4):833–7.  https://doi.org/10.1016/j.urology.2008.09.036.PubMedCrossRefGoogle Scholar
  30. 30.
    Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37.  https://doi.org/10.1016/j.eururo.2014.02.038.PubMedCrossRefGoogle Scholar
  31. 31.
    Ozyigit G, Selek U. Principles and practice of urooncology: radiotherapy, Surgery, and Systemic Therapy. 1st ed. Cham: Springer; 2017.CrossRefGoogle Scholar
  32. 32.
    Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP, Turner SL, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(1):197–207.  https://doi.org/10.1016/j.ijrobp.2003.10.018.PubMedCrossRefGoogle Scholar
  33. 33.
    Fokdal L, Hoyer M, von der Maase H. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol. 2004;43(8):749–57.  https://doi.org/10.1080/02841860410018629.PubMedCrossRefGoogle Scholar
  34. 34.
    Davidson SE, Symonds RP, Snee MP, Upadhyay S, Habeshaw T, Robertson AG. Assessment of factors influencing the outcome of radiotherapy for bladder cancer. Br J Urol. 1990;66(3):288–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Fokdal L, Hoyer M, von der Maase H. Radical radiotherapy for urinary bladder cancer: treatment outcomes. Expert Rev Anticancer Ther. 2006;6(2):269–79.  https://doi.org/10.1586/14737140.6.2.269.PubMedCrossRefGoogle Scholar
  36. 36.
    Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139–44.  https://doi.org/10.1097/01.ju.0000102302.26806.fb.PubMedCrossRefGoogle Scholar
  37. 37.
    Rothwell RI, Ash DV, Jones WG. Radiation treatment planning for bladder cancer: a comparison of cystogram localisation with computed tomography. Clin Radiol. 1983;34(1):103–11.PubMedCrossRefGoogle Scholar
  38. 38.
    Muren LP, Smaaland R, Dahl O. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiother Oncol. 2003;69(3):291–304.PubMedCrossRefGoogle Scholar
  39. 39.
    Turner SL, Swindell R, Bowl N, Marrs J, Brookes B, Read G, et al. Bladder movement during radiation therapy for bladder cancer: implications for treatment planning. Int J Radiat Oncol Biol Phys. 1997;39(2):355–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–9.  https://doi.org/10.1001/jama.294.10.1233.PubMedCrossRefGoogle Scholar
  41. 41.
    Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53(3):595–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Geier M, Astner ST, Duma MN, Jacob V, Nieder C, Putzhammer J, et al. Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy. Strahlenther Onkol. 2012;188(5):410–6.  https://doi.org/10.1007/s00066-012-0081-8.PubMedCrossRefGoogle Scholar
  43. 43.
    Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2009;74(5):1405–18.  https://doi.org/10.1016/j.ijrobp.2008.10.091.PubMedCrossRefGoogle Scholar
  44. 44.
    Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.  https://doi.org/10.1016/j.ijrobp.2007.06.054.PubMedCrossRefGoogle Scholar
  45. 45.
    Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72(3):799–807.  https://doi.org/10.1016/j.ijrobp.2008.01.040.PubMedCrossRefGoogle Scholar
  46. 46.
    Ishii K, Ogino R, Okada W, Nakahara R, Kawamorita R, Nakajima T. A dosimetric comparison of RapidArc and IMRT with hypofractionated simultaneous integrated boost to the prostate for treatment of prostate cancer. Br J Radiol. 2013;86(1030):20130199.  https://doi.org/10.1259/bjr.20130199.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Onal C, Sonmez S, Erbay G, Guler OC, Arslan G. Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy. Br J Radiol. 2014;87(1034):20130617.  https://doi.org/10.1259/bjr.20130617.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Ost P, Speleers B, De Meerleer G, De Neve W, Fonteyne V, Villeirs G, et al. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys. 2011;79(3):920–6.  https://doi.org/10.1016/j.ijrobp.2010.04.025.PubMedCrossRefGoogle Scholar
  49. 49.
    Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, et al. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol. 2009;93(2):213–9.  https://doi.org/10.1016/j.radonc.2009.07.014.PubMedCrossRefGoogle Scholar
  50. 50.
    von Eyben FE, Kiljunen T, Kangasmaki A, Kairemo K, von Eyben R, Joensuu T. Radiotherapy boost for the dominant intraprostatic cancer lesion-a systematic review and meta-analysis. Clin Genitourin Cancer. 2016;14(3):189–97.  https://doi.org/10.1016/j.clgc.2015.12.005.CrossRefGoogle Scholar
  51. 51.
    Lips IM, van der Heide UA, Haustermans K, van Lin EN, Pos F, Franken SP, et al. Single blind randomized phase III trial to investigate the benefit of a focal lesion ablative microboost in prostate cancer (FLAME-trial): study protocol for a randomized controlled trial. Trials. 2011;12:255.  https://doi.org/10.1186/1745-6215-12-255.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;56(4):1093–104.PubMedCrossRefGoogle Scholar
  53. 53.
    Lee WR. Extreme hypofractionation for prostate cancer. Expert Rev Anticancer Ther. 2009;9(1):61–5.  https://doi.org/10.1586/14737140.9.1.61.PubMedCrossRefGoogle Scholar
  54. 54.
    Magnuson WJ, Mahal A, Yu JB. Emerging technologies and techniques in radiation therapy. Semin Radiat Oncol. 2017;27(1):34–42.  https://doi.org/10.1016/j.semradonc.2016.08.004.PubMedCrossRefGoogle Scholar
  55. 55.
    Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol. 2013;31(31):3860–8.  https://doi.org/10.1200/JCO.2013.51.1972.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J Urol. 2015;194(6):1624–30.  https://doi.org/10.1016/j.juro.2015.06.100.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Ozyigit G. The role of radiotherapy in the management of prostate cancer. Turkiye Klinikleri J Med Oncol-Special Topics. 2015;8(3):23–30.Google Scholar
  58. 58.
    Ozdemir Y, Akyol F, Ozyigit G, Hurmuz P, Onal C, Selek U, Karabulut E. Three dimensional conformal radiotherapy and androgen deprivation therapy in patients with clinically localized prostate cancer; Hacettepe University experience. Int J Hematol Oncol. 2015;25(2):107–17.CrossRefGoogle Scholar
  59. 59.
    Ozyigit G, Akyol F, Onal C, Sari S, Gurdalli S, Yapici B. Combined Hormonotherapy and Definitive Radiation Therapy in Localized Prostate Adenocarcinoma. Turk Hematoloji-Onkoloji Dergisi. 2003;13(4):177–89.Google Scholar
  60. 60.
    Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial radiation therapy oncology group 85-31. J Clin Oncol. 2005;23(4):800–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585–91.PubMedCrossRefGoogle Scholar
  62. 62.
    Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–504.PubMedCrossRefGoogle Scholar
  63. 63.
    Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.PubMedCrossRefGoogle Scholar
  64. 64.
    Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst. 2000;92:1731–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Dirix P, Haustermans K, Junius S, Withers R, Oyen R, Van Poppel H. The role of whole pelvic radiotherapy in locally advanced prostate cancer. Radiother Oncol. 2006;79(1):1–14.PubMedCrossRefGoogle Scholar
  66. 66.
    Asbell SO, Martz KL, Shin KH, Sause WT, Doggett RL, Perez CA, et al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998;40(4):769–82.PubMedCrossRefGoogle Scholar
  67. 67.
    Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21(10):1904–11.PubMedCrossRefGoogle Scholar
  68. 68.
    Roach M, Yan Y, Lawton CA, Hsu IJ, Lustig RA, Jones CU, et al. Radiation Therapy Oncology Group (RTOG) 9413: randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT). J Clin Oncol. 2012;30(5_suppl):96.CrossRefGoogle Scholar
  69. 69.
    Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25(34):5366–73.PubMedCrossRefGoogle Scholar
  70. 70.
    Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E, Wagner JP, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys. 2016;96(4):759–69.PubMedCrossRefGoogle Scholar
  71. 71.
    Murthy V, Lewis S, Sawant M, Paul SN, Mahantshetty U, Shrivastava SK. Incidental dose to pelvic nodal regions in prostate-only radiotherapy. Technol Cancer Res Treat. 2017;16(2):211–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. Int J Radiat Oncol Biol Phys. 2005;63(3):800–11.PubMedCrossRefGoogle Scholar
  73. 73.
    Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995;37(1):35–42.PubMedCrossRefGoogle Scholar
  74. 74.
    Zelefsky MJ, Crean D, Mageras GS, Lyass O, Happersett L, Ling CC, et al. Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol. 1999;50(2):225–34.PubMedCrossRefGoogle Scholar
  75. 75.
    Malone S, Crook JM, Kendal WS, Szanto J. Respiratory-induced prostate motion: quantification and characterization. Int J Radiat Oncol Biol Phys. 2000;48(1):105–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078–101.PubMedCrossRefGoogle Scholar
  77. 77.
    Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Measurements. ICoRUa. ICRU report 50: prescribing, recording and reporting photon beam therapy. Bethesda, MD: Measurements. ICoRUa; 1993.Google Scholar
  79. 79.
    Measurements. ICoRUa. ICRU report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD: Measurements. ICoRUa; 1999.Google Scholar
  80. 80.
    Roach M 3rd, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;35(5):1011–8.PubMedCrossRefGoogle Scholar
  81. 81.
    Kagawa K, Lee WR, Schultheiss TE, Hunt MA, Shaer AH, Hanks GE. Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1997;38(2):319–25.PubMedCrossRefGoogle Scholar
  82. 82.
    Rasch C, Barillot I, Remeijer P, Touw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys. 1999;43(1):57–66.PubMedCrossRefGoogle Scholar
  83. 83.
    Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am. 1975;2(1):105–24.PubMedGoogle Scholar
  84. 84.
    Wise AM, Stamey TA, McNeal JE, Clayton JL. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60(2):264–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151(5):1283–90.PubMedCrossRefGoogle Scholar
  86. 86.
    McLaughlin PW, Evans C, Feng M, Narayana V. Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys. 2010;76(2):369–78.PubMedCrossRefGoogle Scholar
  87. 87.
    Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013;111(1):22–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys. 2002;54(3):686–97.PubMedCrossRefGoogle Scholar
  89. 89.
    Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol. 2006;79(3):259–69.PubMedCrossRefGoogle Scholar
  90. 90.
    Qi X, Gao XS, Asaumi J, Zhang M, Li HZ, Ma MW, et al. Optimal contouring of seminal vesicle for definitive radiotherapy of localized prostate cancer: comparison between EORTC prostate cancer radiotherapy guideline, RTOG0815 protocol and actual anatomy. Radiat Oncol. 2014;9:288.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Buyyounouski MK, He P, Jr RA, Feigenberg SJ, Pollack A, Prostate IMRT. In: Bortfeld TS-UR, De Neve W, Wazer DE, editors. Image-guided IMRT. Berlin: Springer; 2006. p. 391–410.CrossRefGoogle Scholar
  92. 92.
    Desai NZM. Prostate Adenocarcinoma. In: Lee NY, et al., editors. Target volume delineation and field setup, a practical guide for conformal and intensity-modulated radiation therapy. Berlin: Springer; 2013. p. 213–26.Google Scholar
  93. 93.
    Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(9485):572–8.PubMedCrossRefGoogle Scholar
  94. 94.
    Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25(27):4178–86.PubMedCrossRefGoogle Scholar
  95. 95.
    Swanson GPTI, Tangen C. Phase III randomized study of adjuvant radiation therapy versus observation in patients with patohologic T3 prostate cancer (SWOG 8794). Int J Radiat Oncol Biol Phys. 2005;63(Suppl 1):S1.CrossRefGoogle Scholar
  96. 96.
    Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus ‘wait and see’ (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol (Meeting Abstracts). 2005;23(16_suppl):4513.CrossRefGoogle Scholar
  97. 97.
    Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders SC, et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the cancer of the prostate strategic urologic research endeavor database. J Urol. 2001;165(3):851–6.PubMedCrossRefGoogle Scholar
  98. 98.
    Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol. 2007;84(2):121–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Wiltshire KL, Brock KK, Haider MA, Zwahlen D, Kong V, Chan E, et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;69(4):1090–9.PubMedCrossRefGoogle Scholar
  100. 100.
    Sidhom MA, Kneebone AB, Lehman M, Wiltshire KL, Millar JL, Mukherjee RK, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol. 2008;88(1):10–9.PubMedCrossRefGoogle Scholar
  101. 101.
    De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, De Neve W. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol. 2005;75(3):325–33.PubMedCrossRefGoogle Scholar
  102. 102.
    Miralbell R, Mollà M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, Sanz S, Ares C, Jorcano S, Linero D, Escudé L. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys. 2010;78(1):50–7.PubMedCrossRefGoogle Scholar
  103. 103.
    Ippolito E, Mantini G, Morganti AG, Mazzeo E, Padula GDA, Digesù C, Cilla S, Frascino V, Luzi S, Massaccesi M, Macchia G, Deodato F, Mattiucci GC, Piermattei A, Cellini N. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion. Am J Clin Oncol. 2012;35(2):158–62.PubMedCrossRefGoogle Scholar
  104. 104.
    Pinkawa M, Piroth MD, Holy R, Klotz J, Djukic V, Corral NE, Caffaro M, Winz OH, Krohn T, Mottaghy FM, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer–evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiat Oncol. 2012;7(1):14.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Aluwini S, van Rooij P, Hoogeman M, Kirkels W, Kolkman-Deurloo I-K, Bangma C. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol. 2013;8(1):84.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Onal C, Sonmez S, Erbay G, Guler OC, Arslan G. Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy. Br J Radiol. 2014;87(1034):20130617.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, Benassi M, Strigari L. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79(4):1013–21.PubMedCrossRefGoogle Scholar
  108. 108.
    Hoffman KE, Ranh Voong K, Levy LB, Allen PK, Choi S, Schlembach PJ, Lee AK, McGuire SE, Nguyen Q, Pugh TJ, Frank SJ, Kudchadker RJ, Du W, Kuban DA. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. J Clin Oncol. 2018;36(29):2943–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Norkus D, Karklelyte A, Engels B, Versmessen H, Griskevicius R, De Ridder M, Storme G, Aleknavicius E, Janulionis E, Valuckas K. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiat Oncol. 2013;8(1):206.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Wilkins A, Mossop H, Syndikus I, Khoo V, Bloomfield D, Parker C, Logue J, Scrase C, Patterson H, Birtle A, Staffurth J, Malik Z, Panades M, Eswar C, Graham J, Russell M, Kirkbride P, O’Sullivan JM, Gao A, Cruickshank C, Griffin C, Dearnaley D, Hall E. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2015;16(16):1605–16.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Aluwini S, Pos F, Schimmel E, Krol S, van der Toorn PP, de Jager H, Alemayehu WG, Heemsbergen W, Heijmen B, Incrocci L. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464–74.PubMedCrossRefGoogle Scholar
  112. 112.
    King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, Meier R, Wang J, Kupelian P, Steinberg M, Katz A. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gokhan Ozyigit
    • 1
    Email author
  • Pervin Hurmuz
    • 1
  • Sezin Yuce Sari
    • 1
  • Cem Onal
    • 2
  • Fatih Biltekin
    • 1
  • Melis Gultekin
    • 1
  • Gozde Yazici
    • 1
  • Ozan Cem Guler
    • 3
  • Fadil Akyol
    • 1
  1. 1.Department of Radiation Oncology, Faculty of MedicineHacettepe UniversityAnkaraTurkey
  2. 2.Faculty of Medicine, Department of Radiation OncologyBaşkent UniversityAdanaTurkey
  3. 3.Department of Radiation Oncology, Faculty of MedicineKaradeniz Technical UniversityTrabzonTurkey

Personalised recommendations